Recursion Pharmaceuticals Raises $239 Million And Partners With Bayer For AI Drug Discovery

Startups that want to leverage artificial intelligence in drug discovery are a dime a dozen in today’s biotech landscape. But Recursion Pharmaceuticals, one of the oldest and most established AI drug discovery companies, has found a way to stand out. The company announced on Wednesday morning an oversubscribed series D funding round of $239 million, and a lucrative strategic partnership with pharma giant Bayer. 

Source url: Forbes